IQVIA Holdings Inc. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing is the Annual Report on Form 10-K for IQVIA Holdings Inc. for the fiscal year ended December 31, 2025. IQVIA is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. The company operates with approximately 93,000 employees in over 100 countries. Effective January 1, 2026, the company will reorganize its reportable segments from three to two: Commercial Solutions (combining Technology & Analytics and Contract Sales & Medical) and Research & Development Solutions.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $16,310 million | $15,405 million | +5.9% |
| Net Income | $1,360 million | $1,373 million | -0.9% |
| Diluted EPS | $7.84 | $7.49 | +4.7% |
| Operating Cash Flow | $2,654 million | $2,716 million | -2.3% |
| Total Debt | $15,800 million | $14,045 million | +12.5% |
| Cash & Equivalents | $1,980 million | $1,702 million | +16.3% |
| Effective Tax Rate | 15.8% | 18.0% | -2.2 pts |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5.9% year-over-year, driven by constant currency growth of 4.8%. The Technology & Analytics Solutions segment grew 7.6%, while Research & Development Solutions grew 4.3% despite client caution.
- Profitability: Operating income remained relatively flat at $2,182 million (down slightly from $2,202 million in 2024) due to increased restructuring costs ($105 million vs. $67 million) and higher interest expense ($729 million vs. $670 million).
- Debt Structure: Total indebtedness increased to $15.8 billion. The company issued $2.0 billion in 6.250% Senior Notes due 2032 and refinanced various term loans. Interest expense rose due to higher outstanding debt balances.
- Acquisitions: The company invested $1,714 million (net of cash) in business acquisitions during 2025, adding $1,279 million in goodwill.
- Share Repurchases: The company repurchased 7.4 million shares for $1,244 million in 2025. As of year-end, $1,769 million remained authorized under the repurchase program.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects continued growth driven by the integration of AI ("Healthcare-grade AI") into clinical and commercial operations. The company anticipates the restructured segment reporting will better align with industry evolution. Backlog for Research & Development Solutions increased to $32.7 billion, with approximately $8.3 billion expected to convert to revenue in the next 12 months.
Key Risks and Contingencies:
- Contract Termination: Most R&D contracts can be terminated on 30 to 90 days' notice, creating revenue volatility.
- Regulatory and Data Privacy: The company faces evolving global data protection laws (e.g., GDPR, EU AI Act) and healthcare regulations that could increase compliance costs or limit data access.
- Cybersecurity: As a holder of sensitive health data, the company is exposed to cyberattacks which could disrupt operations and damage reputation.
- Client Concentration: While no single client exceeded 10% of revenue, the top client accounted for approximately 5% in 2025. Consolidation in the biopharmaceutical industry poses a risk of reduced service volume.
Investor Verification Checklist
- Backlog Conversion: Verify the rate at which the $32.7 billion R&D backlog converts to revenue, given the risk of client cancellations.
- Interest Rate Exposure: Assess the impact of variable-rate debt ($5.768 billion) on future earnings, noting that only a portion is hedged.
- Segment Reclassification: Monitor the impact of the January 2026 segment restructuring on future financial reporting and comparability.
- Acquisition Integration: Review the performance of the $1.7 billion in 2025 acquisitions to ensure expected synergies are realized.
- Tax Rate Stability: Confirm the sustainability of the 15.8% effective tax rate amidst global tax law changes (e.g., OECD Pillar Two).